Ahmed, Mehnaz
Malik, Marlene
Teselink, Johannes
Lanctôt, Krista L.
Herrmann, Nathan http://orcid.org/0000-0001-9955-3155
Article History
First Online: 8 April 2019
Compliance with Ethical Standards
:
: No sources of funding were provided for the preparation of this review article.
: Krista L. Lanctôt has received research grants from the National Institute of Aging for “Apathy in Alzheimer’s Disease Methylphenidate Trial II (ADMET II)” and “Escitalopram for Agitation in Alzheimer’s Disease (S-CitAD)”, Alzheimer Drug Discovery Fund, the Alzheimer Society of Canada (Grant 15–17), Alzheimer’s Association, Canadian Institutes of Health Research, AbbVie, Lundbeck, Pfizer, Sanofi-Aventis, Janssen-Ortho Inc., Roche, and Wyeth; and honoraria from Abbvie and Lundbeck. Nathan Herrmann has received research grants from the Alzheimer Drug Discovery Fund, the Alzheimer Society of Canada, the National Institutes of Health, Canadian Institute of Health Research, Lundbeck, and Roche; and consultation fees from Lilly, Merck, and Astellas. Mehnaz Ahmed, Marlene Malik and Johannes Teselink declare they have no conflicts of interest relevant to the content of this review article.